Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.

Mali N, Su F, Ge J, Fan WX, Zhang J, Ma J

BMC endocrine disorders7 Apr 2022Cited by 7 (Europe PMC)

PMID35392872PMCIDPMC8991462DOI10.1186/s12902-022-01006-6PepBankPUB-35392872

Summary

BackgroundThe efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients.MethodsEight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 software were used for analyses and plotting.ResultsA total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6). However, there was no significant difference in BUN and eGFR between the experimental group and the control group.ConclusionsLiraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower UACR with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, UACR was lower with liraglutide than without it in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseUrinary albumin-to-creatinine ratio (UACR)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287201
02HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower serum creatinine with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, serum creatinine was lower with liraglutide than without it in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseSerum creatinine (Scr)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287202
03HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower cystatin C with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, cystatin C was lower with liraglutide than without it in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseCystatin C (Cysc)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287203
04HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower fasting blood glucose with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, fasting blood sugar was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose (FBG)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287204
05HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower postprandial blood glucose with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, blood sugar after meals was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreasePostprandial blood glucose (PBG)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287205
06HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower HbA1c with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, HbA1c was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287206
07HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower BMI with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, BMI was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseBody mass index (BMI)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287207
08HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower TNF-α with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, the inflammation marker TNF-α was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseTNF-α
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287208
09HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed lower IL-6 with liraglutide than in controls.
In plain wordsIn people with diabetic kidney disease, the inflammation marker IL-6 was lower with liraglutide in pooled trials.
Peptide
Liraglutide
Outcome
DecreaseIL-6
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287209
10HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed no significant difference in BUN between liraglutide and controls.
In plain wordsIn people with diabetic kidney disease, BUN did not differ significantly between liraglutide and control groups.
Peptide
Liraglutide
Outcome
No significant changeBlood urea nitrogen (BUN)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
However, there was no significant difference in BUN and eGFR between the experimental group and the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287210
11HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetic nephropathy, pooled trials showed no significant difference in eGFR between liraglutide and controls.
In plain wordsIn people with diabetic kidney disease, eGFR did not differ significantly between liraglutide and control groups.
Peptide
Liraglutide
Outcome
No significant changeEstimated glomerular filtration rate (eGFR)
Study
n: not reported in source
Comparator
Control without liraglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
However, there was no significant difference in BUN and eGFR between the experimental group and the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened.
Show in the study text Report a problemFND-3539287211

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.